Combinatorial androgen receptor targeted therapy for prostate cancer.

Prostatic carcinogenesis is associated with changes in the androgen receptor (AR) axis converting it from a paracrine dependence upon stromal signaling to an autocrine-initiated signaling for proliferation and survival of prostatic cancer cells. This malignant conversion is due to gain of function changes in which the AR activates novel genomic (i.e. transcriptional) and non-genomic signaling pathways, which are not present in normal prostate epithelial cells. During further progression, additional molecular changes occur which allow these unique malignancy-dependent AR signaling pathways to be activated even in the low androgen ligand environment present following androgen ablation therapy. These signaling pathways are the result of partnering the AR with a series of other genomic (e.g. transcriptional co-activators) or non-genomic (e.g. steroid receptor co-activator (Src) kinase) signaling molecules. Thus, a combinatorial androgen receptor targeted therapy (termed CART therapy) inhibiting several points in the AR signaling cascade is needed to prevent the approximately 30,000 US males per year dying subsequent to failure of standard androgen ablation therapy. To develop such CART therapy, a series of agents targeted at specific points in the AR cascade should be used in combination with standard androgen ablative therapy to define the fewest number of agents needed to produce the maximal therapeutic anti-prostate cancer effect. As an initial approach for developing such CART therapy, a variety of new agents could be combined with luteinizing hormone-releasing hormone analogs. These include: (1) 5alpha-reductase inhibitors to inhibit the conversion of testosterone to the more potent androgen, dihydrotestosterone; (2) geldanamycin analogs to downregulate AR protein in prostate cancer cells, (3) 'bulky' steroid analogs, which can bind to AR and prevent its partnering with other co-activators/signaling molecules, and (4) small molecule kinase inhibitors to inhibit MEK, which is activated as part of the malignant AR signaling cascade.

[1]  W. Mckeehan,et al.  Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. , 1992, Molecular endocrinology.

[2]  M. Schell,et al.  Steroid 5α-Reductase Isozymes I and II in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[3]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Kota Takahashi,et al.  The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. , 2005, The Journal of clinical endocrinology and metabolism.

[5]  D. Tindall,et al.  Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.

[6]  A. Renshaw,et al.  Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. , 2004, Journal of the National Cancer Institute.

[7]  J. Deslypere,et al.  Testosterone and 5α-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene , 1992, Molecular and Cellular Endocrinology.

[8]  Shihua Sun,et al.  Changes in Androgen Receptor Nongenotropic Signaling Correlate with Transition of LNCaP Cells to Androgen Independence , 2004, Cancer Research.

[9]  祝夫 野々村 Growth-stimulatory effect of androgen-induced autocrine growth factor(s) secreted from Shionogi carcinoma 115 cells on androgen-unresponsive cancer cells in a paracrine mechanism , 1990 .

[10]  B. Chatterjee,et al.  Catalytic cleavage of the androgen receptor messenger RNA and functional inhibition of androgen receptor activity by a hammerhead ribozyme. , 1998, Molecular endocrinology.

[11]  J. Thrasher,et al.  Small-interfering RNA–induced androgen receptor silencing leads to apoptotic cell death in prostate cancer , 2005, Molecular Cancer Therapeutics.

[12]  K. Tomer,et al.  Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer , 2005, Clinical Cancer Research.

[13]  W. Isaacs,et al.  Androgen receptor outwits prostate cancer drugs , 2004, Nature Medicine.

[14]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[15]  E. Sausville,et al.  Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance , 2005, Cancer Chemotherapy and Pharmacology.

[16]  Jonathan Greer,et al.  The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain , 2003, Journal of Biological Chemistry.

[17]  Bin He,et al.  Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. , 2004, Molecular cell.

[18]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5α‐reductase inhibitor, SK&F 105657 , 1992 .

[19]  R. Fletterick,et al.  The Molecular Mechanisms of Coactivator Utilization in Ligand-dependent Transactivation by the Androgen Receptor* , 2005, Journal of Biological Chemistry.

[20]  J. Isaacs,et al.  Response of rat and human prostatic cancers to the novel 5 alpha-reductase inhibitor, SK&F 105657. , 1992, The Prostate.

[21]  R. Dahiya,et al.  Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system , 2001, Cell Death and Differentiation.

[22]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[23]  P. Stattin,et al.  Castration‐induced epithelial cell death in human prostate tissue is related to locally reduced IGF‐1 levels , 2007, The Prostate.

[24]  M. Loda,et al.  Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. , 2001, Molecular endocrinology.

[25]  J. Isaacs,et al.  Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). , 1999, Cancer research.

[26]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[27]  J. Isaacs,et al.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. , 2001, Cancer research.

[28]  J. Isaacs,et al.  In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue , 2004, Journal of cellular biochemistry.

[29]  J. Isaacs,et al.  Enhanced Redundancy in Akt and Mitogen-activated Protein Kinase-induced Survival of Malignant versus Normal Prostate Epithelial Cells , 2004, Cancer Research.

[30]  A. Weeraratna,et al.  Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  A. D. De Marzo,et al.  Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? , 2003, The Journal of clinical endocrinology and metabolism.

[32]  Z. Hall Cancer , 1906, The Hospital.

[33]  J. Isaacs,et al.  Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. , 1992, Cancer research.

[34]  D. Neal,et al.  CD133, a novel marker for human prostatic epithelial stem cells , 2004, Journal of Cell Science.

[35]  J. Isaacs,et al.  Pharmacologic Basis for the Enhanced Efficacy of Dutasteride against Prostatic Cancers , 2006, Clinical Cancer Research.

[36]  L. Sokoll,et al.  Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models , 2003, The Prostate.

[37]  O. Dalesio,et al.  MAXIMUM ANDROGEN BLOCKADE IN ADVANCED PROSTATE-CANCER - AN OVERVIEW OF 22 RANDOMIZED TRIALS WITH 3283 DEATHS IN 5710 PATIENTS , 1995 .

[38]  Qing Yang,et al.  Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival , 2005, Cancer Cell International.

[39]  Bin He,et al.  Melanoma Antigen Gene Protein MAGE-11 Regulates Androgen Receptor Function by Modulating the Interdomain Interaction , 2005, Molecular and Cellular Biology.

[40]  A. Weeraratna,et al.  Rational basis for Trk inhibition therapy for prostate cancer , 2000, The Prostate.

[41]  G. Bartsch,et al.  Expression and function of androgen receptor coactivators in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[42]  B. Segnitz,et al.  The Function of Steroid Hormone Receptors Is Inhibited by the hsp90-specific Compound Geldanamycin* , 1997, The Journal of Biological Chemistry.

[43]  K. Matsumoto,et al.  Growth-stimulatory effect of androgen-induced autocrine growth factor(s) secreted from Shionogi carcinoma 115 cells on androgen-unresponsive cancer cells in a paracrine mechanism. , 1988, Cancer research.

[44]  R. Reiter,et al.  Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. , 2002, Molecular cancer research : MCR.

[45]  Ingo K Mellinghoff,et al.  HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.

[46]  C. Cordon-Cardo,et al.  17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Jason C. Young,et al.  Polypeptide release by Hsp90 involves ATP hydrolysis and is enhanced by the co‐chaperone p23 , 2000, The EMBO journal.

[48]  D. S. Coffey,et al.  Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. , 1998, The American journal of pathology.

[49]  Weiqin Lu,et al.  Erratum: Fibroblast growth factor-10. A second candidate stromal to epithelial cell andromedin in prostate (Journal of Biological Chemistry (1999) 274 (12827-12834)) , 1999 .

[50]  N. Rosen,et al.  Synthesis and evaluation of geldanamycin-testosterone hybrids. , 2000, Bioorganic & medicinal chemistry letters.

[51]  F. S. French,et al.  Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer* , 2004, Journal of Biological Chemistry.

[52]  M. Loda,et al.  Intermediate basal cells of the prostate: In vitro and in vivo characterization , 2003, The Prostate.

[53]  H. Klocker,et al.  Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor , 2002, Cancer Gene Therapy.

[54]  W. Ellis,et al.  Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. , 1985, Cancer research.

[55]  M. Ratain,et al.  Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor , 2004, Investigational New Drugs.

[56]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[57]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[58]  J. Isaacs,et al.  Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells. , 1998, Cancer research.

[59]  Desok Kim,et al.  The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.

[60]  A. Bilancio,et al.  Rapid signalling pathway activation by androgens in epithelial and stromal cells , 2004, Steroids.

[61]  S. Balk,et al.  The Androgen Receptor Recruits Nuclear Receptor CoRepressor (N-CoR) in the Presence of Mifepristone via Its N and C Termini Revealing a Novel Molecular Mechanism for Androgen Receptor Antagonists* , 2005, Journal of Biological Chemistry.